Cutting Edge Information

Ongoing training is a critical component of successful regulatory compliance. Consulting firm Cutting Edge Information found that online compliance training is more efficient, builds clearer accountability, ... read more

With greater economic pressures and more competition for many products, private and governmental payers require clear and thorough data to prove that a new treatment’s clinical benefits justify ... read more

The transition from discovery and development to drug commercialization requires an entirely different set of skills, as both large and small pharmaceutical and biotech companies have found. And ... read more

The relationship between pharmaceutical companies and the payer organizations that determine how drugs will be paid for has often been adversarial and sometimes tense. But earlier communication between ... read more

Pharmaceutical market access teams have often found it difficult to find a single, stable position within their companies’ structure and org charts. Market access teams have a wide ... read more

Patient adherence teams for many drug brands are boosting spending this year on new digital tools in a bid to better reach patients and drive higher patient adherence. ... read more

Drug and device companies are still waiting for the U.S. Centers for Medicare and Medicaid Services (CMS) to issue its final ruling on how it will implement the ... read more

Pharmaceutical brand teams are generally dissatisfied with their outsourced digital marketing, according to a study by Cutting Edge Information. However, the need to make agency relationships successful ... read more

The rapid growth of Phase IV clinical trials has meant expanded budgets for post-marketing studies and a subsequent need to manage complex outsourcing relationships. ... read more

Medical science liaisons’ role in building key opinion leader relationships and managing scientific information continues to change and grow substantially. Reflecting this change, pharmaceutical and ... read more

U.S. payers have traditionally been more open than their European counterparts when evaluating new treatments for formulary approval and reimbursement. But a new survey finds that U.S. market ... read more

Pharmaceutical companies now use a wider variety of tools to support healthy portfolios and extend product life, reflecting the shift as portfolio teams have refined their recipes for ... read more

Pharmaceutical and biotech companies using direct-to-consumer (DTC) advertising, such as television and magazine ads, report generating 14 percent more revenue than they would if they discontinued DTC ... read more

Pharmaceutical brand teams’ budgets for U.S. patient adherence programs more than doubled this year, rising on average from $613,000 to $1.5 million, according to a study of brands ... read more

The growth of continuing medical education events as a marketing tool in emerging markets is mirrored by a recent drop in CME sponsorship in the United States, according ... read more

Almost half of drug research companies pay between $1 million and $5 million to develop targeted therapeutic technologies that increase the effectiveness of drugs in development. Another third ... read more

The rapid increase in reference pricing’s utilization rate means events that would have been localized to one market in the past now have ripple effects worldwide, according to ... read more

The roles and responsibilities of Medical science liaisons (MSLs) to support their teams’ scientific and clinical missions are evolving rapidly. The pace of change requires companies to better ... read more

Companies seeking to out-license a drug in clinical development will spend an average of $86,000 to identify buyers, according to a recent benchmarking study by pharmaceutical research firm ... read more

Phase IV clinical programs that are housed within a company’s Clinical Development structure often compete directly with the company’s own pre-launch clinical programs for patients, budget resources and ... read more